Trial Profile
Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jun 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Plerixafor (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2017 Status changed from active, no longer recruiting to completed.
- 31 Jul 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 18 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.